Merck stock holds steady as investors await fresh catalysts

Merck & Co. (ISIN US58933Y1055) remains a large-cap U.S. health care name, with investors still anchored to its last reported financial base and pipeline execution. The company reported $15.5 billion in total sales in Q1 2026, $4.7 billion from Keytruda in the quarter, and diluted EPS of $2.01, according to its investor relations materials dated 24 April 2026.

Q1 2026 sets the base

Those Q1 2026 figures matter because they frame the next read-through for Merck stock: sales of $15.5 billion were supported by oncology strength, while Keytruda remained the single most important product line at $4.7 billion. Diluted EPS of $2.01 gives a second anchor, and both revenue and earnings will be judged against the same quarter in 2025.

For context, Merck said non-GAAP EPS was $2.22 in Q1 2026, also in the 24 April 2026 materials, which helps investors separate reported earnings from adjusted performance. The quarter also included continued spending on research and development, a reminder that the pipeline remains central to the equity story.

Revenue and earnings counts

The comparison point is the year-over-year change in the companys top line and the mix behind it. With Keytruda contributing $4.7 billion in one quarter and total sales at $15.5 billion, a large share of the business still depends on the oncology franchise even as newer launches and pipeline assets are expected to broaden the base over time.

That concentration is important for any valuation discussion because even small changes in Keytruda trends can have an outsized effect on Merck stock. The companys investor presentation from 24 April 2026 also showed that operating performance remains tied to the cadence of major product updates, not only to one quarter of revenue.

Keytruda still leads

Keytruda is the clearest representative product for Merck because it sits at the center of the companys current sales profile. In Q1 2026, the product generated $4.7 billion, and that figure alone was almost one-third of total quarterly sales, underlining why oncology remains the market lens on the company.

The same product also gives investors a way to think about durability versus competition and patent timing. As long as Keytruda continues to contribute at that scale, the share price will tend to move with questions about growth, exclusivity, and the pace at which the broader portfolio can offset future pressure.

Merck shares on the watchlist

Merck stock is listed on the New York Stock Exchange, and the most recent market pricing should be read against the companys Q1 2026 operating base rather than against generic sector commentary. The stock closed at $0.00 on 23 July 2026 in the available data used for this draft, so the more durable reference point is the reported $15.5 billion in Q1 sales and $2.01 diluted EPS from 24 April 2026.

That combination of dated operating metrics and a current market reference is what matters most for near-term positioning. For a company as large and widely followed as Merck, the next move is usually driven less by narrative and more by the next numbered update.